
==== Front
ACS OmegaACS OmegaaoacsodfACS Omega2470-1343American Chemical Society 3002368510.1021/acsomega.7b00490ArticleTautomeric-Dependent Lactam Cycloaddition with Nitrile Oxide: Facile Synthesis
of 1,2,4-Oxadiazole[4,5-a]indolone Derivatives Jiang Kun-Ming †Luesakul Urarika ‡§Zhao Shu-Yue †An Kun †Muangsin Nongnuj §Neamati Nouri *‡Jin Yi *†‡Lin Jun *†† Key
Laboratory of Medicinal Chemistry for Natural Resource, Ministry of
Education, School of Chemical Science and Technology, Yunnan University, Kunming 650091, P. R. China‡ Department
of Medicinal Chemistry, College of Pharmacy, and Translational Oncology
Program, University of Michigan, Ann Arbor, Michigan 48109, United States§ Department
of Chemistry, Faculty of Science, Chulalongkorn
University, Bangkok 10330, Thailand* E-mail: neamati@umich.edu (N.N.).* E-mail: jinyi@ynu.edu.cn (Y.J.).* E-mail: linjun@ynu.edu.cn. Phone/Fax: +86 871 65031633 (J.L.).03 07 2017 31 07 2017 2 7 3123 3134 21 04 2017 19 06 2017 Copyright © 2017 American Chemical
Society2017American Chemical
SocietyThis is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.

A concise, metal-free, and gram-scale
strategy to convert indoline-2,3-diones
to 1,2,4-oxadiazole[4,5-a]indolones through an improved
[3 + 2] cycloaddition of α-ketone-lactam with nitrile oxides
has been developed. The lactim form of the resonance structure of
isatin in protic solvents is the key active dipolarophile that shows
chemo- and regioselectivity under experimental and theoretical conditions.
This strategy conveniently enabled the assembly of several 1,2,4-oxadiazole[4,5-a]indolines with a broad range of functional groups. Compounds 3a and 4b exhibit cytotoxicity in the NCI/ADR-RES,
SKOV3, and OVCAR8 cell lines.

document-id-old-9ao7b00490document-id-new-14ao-2017-004906ccc-price
==== Body
Introduction
Lactams (−NH–CO−)
are commonly present in
many natural products such as isatins, uracils, and purines. Previous
experiments1 and quantum chemistry2 studies have confirmed that lactams have the
resonance structure of lactims [−N=C(OH)−] and
the tautomeric ratios3 that depend on temperature,
solvent, and pH. The C=N double bond of lactim is similar to
the C=N moiety of the imine or the imidate ester. In 2012,
Jay4 reported the cycloaddition of nitrile
imines with an α,β-unsaturated
lactam; however, the reactive dipolarophile is an α,β-unsaturated
C=C double bond rather than a lactam. Using lactam as a tautomeric
dipolarophile (lactim) incorporated with nitrile oxide to prepare
a heteropolycyclic system has not been investigated previously (Scheme 1c).

Scheme 1 Synthetic
Strategies toward 1,2,4-Oxadiazoles: (a) Common Methods
Based on Nitrile. (b) Example of Modern 1,2,4-Oxadiazole Synthesis
and (c) Present Work
1,2,4-Oxadiazoles are important building blocks5 found in natural6 and
synthesized
products, and they are often used in medicinal chemistry7 and material sciences.8 There are several 1,2,4-oxadiazole pharmaceutical products (Figure 1), such as Translarna,9 used for the treatment of Duchenne muscular dystrophy
and cystic fibrosis. Several 1,2,4-oxadiazoles were reported to have
antimicrobial, antipsychotic,7a antitumor,7b anticonvulsant,7c antithrombotic, and anti-Alzheimer’s disease7a properties. They are also used in liquid crystals,8b organic light-emitting diodes (OLEDs),8d and fluorogenic chemosensory8a and high-energy materials.8c

Figure 1 Select
examples of biologically active 1,2,4-oxadiazole compounds.

In general, there are two examples
of [3 + 2] and modified [4 +
1] strategies to synthesize 1,2,4-oxadiazoles,10 both of which involve a nitrile as a key synthon (Scheme 1a). One pathway exploits
the 1,3-dipolar cycloaddition of nitriles with nitrile oxides to directly
produce 1,2,4-oxadiazoles [Scheme 1a(1)]. Another major route is based on the prefunctionalization
of the nitrile to an amidoxime prepared by the reaction with hydroxylamine
and the subsequent reaction with a wide variety of activated substrates,
such as carboxylic acids, esters, acid chlorides, or the amidoxime
itself, which leads to the formation of 1,2,4-oxadiazoles upon heating
[Scheme 1a(2)]. Recent
syntheses of 1,2,4-oxadiazoles have focused on alternative methodologies
developed to generate only particularly reactive precursors in situ
(Scheme 1b).11 Some catalytic pathways have also been exploited
to assist the cyclization step or even the initial O-acylation of
the amidoxime.12 However, these reactions
require organometallics, strongly acidic or basic conditions, and
high temperatures that lead to low yields and complicated workups.
Reported syntheses of 1,2,4-oxadiazole[4,5-a]indolones
are quite rare.13 During the early development
of this chemistry, Miller and Scrowston13a reported the syntheses of 9a-ethoxy-9,9a-dihydro-3-(aryl)-1,2,4-oxadiazolo[4,5-a]indol-9-one in 28–62% yield, by reacting nitrile
oxides generated in situ in benzene with prefabricated 2-ethoxy-1H-indol-2-one. Other works attempted to increase the reactivity
of the C=N double bond of dipolarophiles in imines (−C=N−)13f−13h or imidate esters [−(EtO)C=N−]13j−13l by the prefunctionalization of indolines or imidazoles. The starting
materials, such as 2,3,3-trimethyl-3H-indole, are
limited because of synthetic difficulties. Little advancement has
been made toward the development
of a general and reliable method for the synthesis of 1,2,4-oxadiazole[4,5-a]indolones using nitrile oxide dipolar cycloaddition chemistry.
Thus, efforts to modernize the synthetic methods are certainly necessary.
Isatin represents the first recognized case14 of having tautomeric forms of lactam and lactim. Moreover, most
of the substituted isatins are readily accessible.15 In the present work, we not only explored a new, green,
efficient, and chemoselective approach to obtain 1,2,4-oxadiazole[4,5-a]indolines but also developed a new type of potentially
bioactive heterocyclic system.

Results and Discussion
We initially
attempted to react indoline-2,3-dione (2a) with in situ-generated
nitrile oxide via a fluoride ion16-mediated
dehydrochlorination of the N-hydroximoyl chloride
(1a). However, both
CsF and tetra-n-butylammonium fluoride (TBAF) yielded the dimerized
products (6) of phenyl nitrile oxide in aprotic solvents
(Table 1, entry 1–2)
such as tetrahydrofuran (THF) and dichloromethane (DCM). The less
expected compound 3a (entry 3–4, 34%, 31%) was
formed in EtOH or MeOH (detected by high-resolution high-performance
liquid chromatography–mass spectrometry (HPLC–MS) and
proton nuclear magnetic resonance (1H NMR)). When the reaction
was mediated by other organic bases such as Et3N and N,N-diisopropylethylamine (DIPEA) instead
of the fluoride ion, the yield of 3a was significantly
increased in EtOH (entry 7, 12, 73%, 71%) and MeOH (entry 8, 13, 76%,
73%). Meanwhile, dimer 6 was still the main product in
THF and DCM (entry 5, 6, 10, 11). These results suggest that the protic
solvents can promote the cycloaddition of nitrile oxide with isatin.
In addition, an attempt to elevate reaction temperature to increase
the rate of [3 + 2] cycloaddition was not successful (entry 9). This
may be due to the decomposition of product 3a and dimer 6 under high temperature. Other solvents, such as isopropanol,
water, dioxane, and dimethylformamide (DMF) were screened to optimize
the [3 + 2] cycloaddition conditions (entry 14–17). To our
surprise, the reaction proceeded well to obtain a high yield (70%)
of 3a in water (entry 15) and a very high yield (84%)
of 3a in isopropanol (entry 14). Further screening using
NaHCO3 as a base produced a high yield (72%) of 3a (entry 18). Notably, the cycloaddition reaction can proceed in water,
MeOH, EtOH, or isopropanol without any base to obtain a low to moderate
yield (40–56%) of 3a (entry 21–24).

Table 1 Optimization Conditions for the Reaction
of Indoline-2,3-dione (2a) and N-Hydroximoyl
Chloride (1a)a
 	 	 	 	 	yield
(%)b	
entry	base	solvent	Time (h)	t (°C)	3a	6	
1	CsF	THF	10	rt	3	86	
2	CsF	DCM	10	rt	3	90	
3	CsF	EtOH	10	rt	34	65	
4	TBAF	MeOH	10	rt	31	68	
5	Et3N	THF	10	rt	6	78	
6	EtE3N	DCM	10	rt	5	80	
7	Et3N	EtOH	10	rt	73	11	
8	Et3N	MeOH	10	rt	76	15	
9	Et3N	MeOH	10	80 °C	30	8	
10	DIPEA	THF	10	rt	4	79	
11	DIPEA	DCM	10	rt	5	78	
12	DIPEA	EtOH	10	rt	71	10	
13	DIPEA	MeOH	10	rt	73	13	
14	Et3N	isopropanol	5	rt	84	9	
15	Et3N	waterc	5	rt	70	11	
16	Et3N	dioxane	5	rt	6	86	
17	Et3N	DMF	5	rt	9	89	
18	NaHCO3	waterc	5	rt	72	12	
19	NaHCO3	isopropanol	5	rt	68	13	
20	NaHCO3	EtOH	5	rt	65	11	
21	d	waterc	5	rt	56	12	
22	d	EtOH	5	rt	45	19	
23	d	MeOH	5	rt	40	11	
24	d	isopropanol	5	rt	41	12	
a General conditions: hydroxybenzimidoyl
chloride (1a, 0.6 mmol, 1.2 equiv), indoline-2,3-dione
(2a, 0.5 mmol), base (1.0 mmol, 2 equiv), and solvent
(15 mL).

b Isolated yield
based on 2a.

c Water/isopropanol = 95:5.

d No base was used.

To explore
the cause of 1,2,4-oxadiazole[4,5-a]indolone production
by isatin and nitrile oxide in different solvents, we first utilized
the equilibrium constant17Kn of tautomerization for isatin (Figure 2a, the lactam form,
the lactim form, and the imide form) to understand the origins of
the reactivity difference in various solvents. The values of Kcacula and Kcaculb calculated by the density functional theory
analysis are listed in Table S1. The experimental
value of Kexp.a was also obtained from the 1H NMR
(Figure 2c) of isatin
in different solvents. Table S1 shows that
the Kcacula values in protic solvents are almost 1000
times greater than those in aprotic solvents; for example, Kcacula in D2O and CD3Cl are 0.13 and 4.89 ×
10–3, respectively. These results are consistent
with the experimental Kexp.a values (Kexp.a in D2O and CDCl3 is 0.18 and 0, respectively). Meanwhile, Kcaculb in seven solvents is less than 5.00 × 10–4, indicating that it is difficult for the imine tautomer of isatin
to survive in protic and aprotic solvents. These results suggest that
the lactim tautomer of isatin is more likely to react with nitrile
oxide when the lactam form and lactim form coexist in the solvent.

Figure 2 (a) Tautomerization
of isatin and (b) 1H NMR of isatin
in CD3OD and dimethyl sulfoxide (DMSO)-d6 solvent.

On the other hand, there are two regioisomeric pathways (Figure 3, ortho and meta)
for nitrile oxide to react with dipolarophile isatin. The cycloaddition
of isatin lactim form 2a′ with nitrile oxide in
the ortho attack via the transition state TSortho leads
to product 3a. Similarly, the cycloaddition of isatin
lactim-form 2a′ with nitrile oxide in the meta
attack via the transition state TSmeta leads to product 3a′. The corresponding structures and energy profiles
are given in Figure 3. As expected, the ortho-cyclization mode is more favorable than
the meta mode by about 11.55 kcal·mol–1. Therefore,
this cycloaddition shows complete ortho regioselectivity. These results
are in agreement with the experimental data in Table 1.

Figure 3 Energy profile in kcal·mol–1 for the 1,3-dipolar
cycloaddition reaction between the dipolarophile 1a′ and the dipole 2a′.

Under optimal conditions, hydroxybenzimidoyl chloride (24
mmol,
1.2 equiv)/indoline-2,3-dione (20 mmol)/isopropanol/rt/Et3N (2.0 equiv) over 5 h and various N-hydroximoyl
chlorides with electron-deficient or electron-rich groups were selected
to investigate the scope of the [3 + 2] cycloaddition reaction. Both
electron-rich and electron-deficient nitrile oxide precursors successfully
participated in the [3 + 2] cycloaddition to provide 1,2,4-oxadiazolo[4,5-a]indol-9(9aH)-one (Table 2, 3a–4j). Higher yields
were observed when R2 = H and N-hydroximoyl
chlorides with electron-deficient substrates were used (Table 2, 3b, 3i, 3j, 3k, 3m, with 88, 88,
86, 85, 89% isolated yield), whereas electron-rich methyl or methoxy
provided moderate to low yields (Table 2, 3b–3f). In general, the position
of the functional group on the aromatic ring did not affect the reaction
(Table 2, 3c, 3f–3h). In addition, the aromatic N-hydroximoyl chloride provided 1,2,4-oxadiazolo[4,5-a]indol-9(9aH)-one in good to excellent yields, whereas
the heterocyclic or alkyl substrates gave low yields (Table 2, 3d and 3o).

Table 2 Select Examples of [3 + 2] Cycloaddition
of in Situ-Generated Nitrile Oxides and Indoline-2,3-dionea
entry	1 (R1)	2 (R2)	3	yieldb (%)	
1	1a (Ph)	2a (H)	3a	84	
2	1b (4-F C6H4)	2a (H)	3b	88	
3	1c (4-OCH3 C6H4)	2a (H)	3c	70	
4	1d (i-Pr)	2a (H)	3d	46	
5	1e (4-CH3 C6H4)	2a (H)	3e	77	
6	1f (3-CH3 C6H4)	2a (H)	3f	75	
7	1g (2-CH3 C6H4)	2a (H)	3g	79	
8	1h (4-Et C6H4)	2a (H)	3h	76	
9	1i (3-F C6H4)	2a (H)	3i	88	
10	1j (2-F C6H4)	2a (H)	3j	86	
11	1k (4-Cl C6H4)	2a (H)	3k	85	
12	1l (3-Cl C6H4)	2a (H)	3l	83	
13	1m (2-Cl C6H4)	2a (H)	3m	89	
14	1n (4-Br C6H4)	2a (H)	3n	82	
15	1o (C4H3S)c	2a (H)	3o	64	
16	1a (Ph)	2b (F)	3p	72	
17	1e (4-CH3 C6H4)	2b (F)	3q	69	
18	1c (4-OCH3 C6H4)	2b (F)	3r	70	
19	1b (4-F C6H4)	2b (F)	3s	87	
20	1a (Ph)	2c (OCH3)	3t	87	
21	1e (4-CH3 C6H4)	2c (OCH3)	3u	84	
22	1g (2-CH3 C6H4)	2c (OCH3)	3v	78	
23	1b (4-F C6H4)	2c (OCH3)	3w	96	
24	1j (2-F C6H4)	2c (OCH3)	3x	85	
25	1a (Ph)	2d (CH3)	3y	85	
26	1e (4-CH3 C6H4)	2d (CH3)	3z	82	
27	1g (2-CH3 C6H4)	2d (CH3)	4a	81	
28	1b (4-F C6H4)	2d (CH3)	4b	92	
29	1i (3-F C6H4)	2d (CH3)	4c	89	
30	1j (2-F C6H4)	2d (CH3)	4d	88	
31	1k (4-Cl C6H4)	2d (CH3)	4e	80	
32	1a (Ph)	2e (Br)	4f	83	
33	1e (4-CH3 C6H4)	2e (Br)	4g	81	
34	1g (2-CH3 C6H4)	2e (Br)	4h	82	
35	1b (4-F C6H4)	2e (Br)	4i	87	
36	1k (4-Cl C6H4)	2e (Br)	4j	85	
a General conditions:
hydroxybenzimidoyl
chloride (1, 24 mmol, 1.2 equiv), indoline-2,3-dione
(2, 20 mmol), base (40 mmol, 2 equiv), and isopropanol
(50 mL).

b Isolated yield
based on 2.

c C4H3S = thiophene.

Modification of the electronic properties of the indoline-2,3-dione
substrate was also explored. Electron-donating groups substituted
at C-5 of indoline-2,3-dione were beneficial to the [3 + 2] cycloaddition.
When the electron-donating 5-methoxyindoline-2,3-dione reacted with N-hydroxybenzimidoyl chloride, 3t was obtained
with a good yield (Table 2, 87%). Furthermore, the combination of the electron-rich
indoline-2,3-dione (2c) with the electron-deficient N-hydroxybenzimidoyl chloride (1b) produced 3w with an excellent yield (Table 2, 96%). However, when R2 was an
electron-withdrawing group (e.g., R2 = Br), the reaction
provided a moderate to low yield (Table 2, 3p–3s, 4f–4j).

These different reactant activities for this reaction can
also
be understood by using a frontier molecular orbital (FMO) interaction
energy ΔE. The 1,3-dipole cycloaddition is
controlled by the highest occupied molecular orbital (HOMO) of dipolarophiles
and the lowest unoccupied molecular orbital (LUMO) of dipolars,18a−18c and the chemical reactivity increases with the decrease in the ΔE value (LUMOdipolar – HOMOdipolarophile). Figure 4a shows
the computed molecular orbitals of isatin derivatives (lactim form)
and nitrile oxides, and Figure 4b shows the ΔE between dipolars (1a, 1b, 1c, 1d) and
dipolarophiles (2a, 2b, 2c).
The most electron-rich dipole 1b and the most electron-deficient
dipolarophile 2c give the lowest ΔE to efficiently obtain the cycloaddition product 3w.
On the other hand, the alkyl-substituted nitrile oxide 1d increased the FMO interaction energy, which leads to the reduced
cycloaddition activity of 3d.

Figure 4 (a) Computed LUMOs of
dipoles 1a, 1b, 1c, and 1d and the HOMOs of dipolarophiles 2a, 2b, and 2c in eV and calculated
using B3LYP/6-31G(d,p)/IEFPCM//M06-2X/6-31G(d,p)/IEFPCM and (b) frontier
orbital interaction energy (ΔE = LUMOoxide – HOMOisatin) between dipoles and dipolarophiles
in kcal·mol–1.

Then, we investigated the cycloaddition of tautomeric-dependent
benzouracil and uracil derivatives with nitrile oxide for the synthesis
of 1,2,4-oxadiazole. The nitrile oxide reacted with 5a, 5b, 5c, 5d, and 5e, giving the 1,2,4-oxadiazole derivatives 6a, 6b, 6c, 6d, and 6e with
78, 86, 76, 82, and 89% yields, respectively (Scheme 2 and see 1H and 13C
NMR in the Supporting Information). This tautomeric-dependent cycloaddition could
be employed in either water or alcohol without any base to obtain
specific chemo- and regioselectivity.

Scheme 2 Synthesis of 1,2,4-Oxadiazole
Derivations
Reaction conditions: hydroxybenzimidoyl
chloride (24 mmol, 1.2 equiv)/dipolarophile (20 mmol)/isopropanol/rt/Et3N (2.0 equiv) over 5 h.

The cytotoxicity
of synthetic compounds was determined by the MTT
and the colony formation assays against two human ovarian cancer cell
lines NCI/ADR-RES (an ovarian cancer cell resistant to doxorubicin)
and SKOV3. All compounds were preliminary screened for their cytotoxicity
at 10 μM. The results for 3a and 4b are summarized in Table 3. Further structure–activity relationship (SAR) studies
are ongoing and have been planned to explore the in vitro biological
activities.

Table 3 Cytotoxicity Profile of Compounds
(3a and 4b) against Ovarian Cancer Cell
Lines, by MTT and Colony Assay
a Inhibition rate
(%) at 10 μM.

b Image
of colonies of cells treated
with 3a.

c Image
of colonies of cells treated
with 4b.

d Image
of colonies of cells treated
with (DMSO). Colony formation assay performed to assess the cytotoxic
effects on NCI/ADR-RES cancer cell growth at 10 μM.

Conclusions
In summary, we have
developed an efficient method for 1,2,4-oxadiazole
formation through the [3 + 2] cycloaddition of in situ-generated nitrile
oxides and indoline-2,3-dione. The utility of this strategy was demonstrated
by the preparation of a broad range of functionalized tricyclic heterocycle
containing 1,2,4-oxadiazole in moderate to excellent yields. Potential
advantages of our approach versus previously published methods include
readily available starting materials, metal-free conditions, and reaction
tolerance for broad functional groups. Further applications of this
process are currently underway to design novel biologically active
compounds for cancer.

Experimental Section
General Experimental Methods
All compounds were fully
characterized by infrared (IR), NMR, and high-resolution mass spectrometry
(HRMS). NMR spectra were recorded on a Bruker DRX400 (1H: 400 MHz, 13C: 100 MHz), Bruker DRX500 (1H: 500 MHz, 13C: 125 MHz), or Bruker DRX600 (1H: 600 MHz, 13C: 150 MHz) instruments using deuterated
CDCl3 and DMSO-d6 as solvents.
Chemical shifts (δ) are expressed in parts per million, and J values are given in hertz. IR spectra were recorded on
a Fourier transform infrared (FT-IR) Thermo Nicolet Avatar 360 instrument
using a KBr pellet. Reactions were monitored by thin-layer chromatography
(TLC) using silica gel GF254. The melting points were determined
using an XT-4A melting point apparatus and were uncorrected. HRMS
was performed on an Agilent liquid chromatography/mass selective detector
time-of-flight instrument. All chemicals and solvents were used as
received without further purification, unless otherwise stated. Column
chromatography was performed on silica gel (200–300 mesh).
Benzaldehyde, hydroxylamine hydrochloride, N-chiorosuccinimide,
and indolone (2a–e) were purchased from Adamas-Beta
Corporation Limited.

General Procedure for the Synthesis of Intermediate
Benzaldehyde
Oxime
Substituted benzaldehyde (50 mmol), hydroxylamine hydrochloride
(50 mmol), and K2CO3 (50 mmol) were dissolved
in 50 mL methanol into a 125 mL round-bottom flask. The mixture was
stirred at room temperature for 3 h and monitored by TLC. After the
reaction was completed, the solvent was removed with a rotary evaporator,
and then, water was added to the residue, extracted with ethyl acetate.
The organic phase was dried over anhydrous sodium sulfate, concentrated
by a rotary evaporator to yield intermediate benzaldoxime (90–96%
yield).

General Procedure for the Synthesis of Hydroxybenzimidoyl Chloride 1a–o
Benzaldoxime (50 mmol) and N-chiorosuccinimide (50 mmol) were dissolved in 40 mL DMF and placed
into a 125 mL round-bottom flask, and the mixture was stirred at room
temperature for 2–4 h. The completion of the reaction was monitored
by TLC. Water was added, and the mixture was extracted with ethyl
acetate, dried over Na2SO4, and concentrated
and purified by flash column chromatography to yield the intermediate 1a–o (92–95% yield).

General Procedure for the
Synthesis of 3a–4j
Compound 1a–o (24 mmol), substituted
isatin 2a–e (20 mmol), and Et3N (40
mmol) were dissolved in 50 mL isopropanol and placed into a 125 mL
round-bottom flask and stirred at room temperature for 5 h. Progress
of the reaction was monitored by TLC. The mixture was evaporated by
a rotary evaporator, extracted with ethyl acetate, dried over Na2SO4, and concentrated and purified by flash column
chromatography (petroleum ether/ethyl acetate (PE/EA) = 5:1) to yield
the compound 3a–4j (46–96% yield). The
products were further characterized by FT-IR, NMR, and HRMS and were
in good agreement with the target structures.

9a-Hydroxy-3-phenyl-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (3a)
Yellow
solid; 84% yield; mp = 180.5–182.3 °C; IR (KBr) νmax: 3367, 3212, 3060, 1749, 1627, 1576, 1475, 1448, 1353,
1333, 1286, 1256, 1217, 1160, 1118, 1093, 1070, 1029, 1013, 971, 938,
857, 812, 754, 685, 660, 645, 618, 492 cm–1; 1H NMR (400 MHz, DMSO-d6): δ
10.95 (1H, s), 7.81 (2H, d, J = 7.2 Hz), 7.66–7.46
(5H, m), 7.14–7.10 (1H, m), 6.98 (1H, d, J = 7.6 Hz); 13C NMR (100 MHz, DMSO-d6): δ 170.35, 159.31, 143.75, 134.10, 132.96, 129.77,
127.19, 126.58, 123.74, 121.82, 121.24, 111.91, 106.44; HRMS (ESI+) m/z: calcd for C15H10N2O3Na [M + Na]+ 289.0584;
found 289.0673.

3-(4-Fluorophenyl)-9a-hydroxy-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (3b)
Yellow solid; 88% yield; mp = 193.5–195.8 °C; IR (KBr)
νmax: 3414, 3216, 1752, 1630, 1604, 1512, 1476, 1413,
1354, 1283, 1258, 1240, 1217, 1157, 1118, 1097, 1069, 1018, 966, 941,
864, 840, 812, 754, 719, 689, 660, 625, 506, 493 cm–1; 1H NMR (400 MHz, DMSO-d6): δ 10.95 (1H, s), 7.89–7.85 (2H, m), 7.61 (1H, d, J = 7.2 Hz), 7.50–7.39 (3H, m), 7.12 (1H, t, J = 7.6 Hz), 6.98 (3H, d, J = 7.6 Hz); 13C NMR (100 MHz, DMSO-d6): δ
170.28, 166.03, 163.54, 158.64, 143.76, 134.12, 129.99, 129.90, 126.61,
123.73, 121.13, 118.41, 117.18, 116.96, 111.91, 106.56; HRMS (ESI+) m/z: calcd for C15H9FN2O3Na [M + Na]+ 307.0489;
found 307.0501.

9a-Hydroxy-3-(4-methoxyphenyl)-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (3c)
Yellow solid; 70% yield; mp = 196.2–198.3 °C; IR (KBr)
νmax: 3437, 3161, 3104, 2838, 1738, 1626, 1607, 1513,
1474, 1423, 1346, 1309, 1283, 1256, 1221, 1177, 1118, 1091, 1069,
1019, 1004, 971, 926, 835, 815, 759, 722, 688, 666, 643, 625, 611,
563, 518, 502, 486, 471, 456, 422 cm–1; 1H NMR (600 MHz, DMSO-d6): δ 10.92
(1H, s), 7.75–7.74 (2H, m), 7.58 (1H, d, J = 7.4 Hz), 7.48 (1H, t, J = 7.8 Hz), 7.13–7.10
(3H, m), 6.98 (1H, d, J = 7.8 Hz), 3.84 (3H, s); 13C NMR (150 MHz, DMSO-d6): δ
170.50, 162.81, 159.17, 143.72, 133.99, 129.11, 126.48, 123.71, 123.21,
121.43, 115.22, 113.87, 111.87, 106.11, 56.00; HRMS (ESI+) m/z: calcd for C16H12N2O4Na [M + Na]+ 319.0689;
found 319.0692.

9a-Hydroxy-3-isopropyl-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (3d)
Yellow
solid; 46% yield; mp = 111.2–112.5 °C; IR (KBr) νmax: 3550, 3475, 3412, 3303, 2978, 2938, 2879, 1751, 1717,
1622, 1471, 1384, 1331, 1300, 1244, 1198, 1158, 1121, 1074, 1037,
971, 943, 879, 829, 811, 767, 690, 615, 489 cm–1; 1H NMR (400 MHz, DMSO-d6): δ 10.83 (1H, s), 7.49–7.43 (2H, m), 7.10 (1H, t, J = 7.6 Hz), 6.94 (1H, d, J = 8.0 Hz),
2.89–2.82 (1H, m), 1.22 (6H, d, J = 7.2 Hz); 13C NMR (100 MHz, DMSO-d6): δ
170.53, 165.18, 143.44, 133.71, 126.06, 123.60, 121.92, 111.75, 105.49,
24.68, 19.07, 19.03; HRMS (ESI+) m/z: calcd for C12H12N2O3Na [M + Na]+ 255.0740; found 255.0742.

9a-Hydroxy-3-(4-tolyl)-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (3e)
Yellow
solid; 77% yield; mp = 160.7–162.9 °C; IR (KBr) νmax: 3438, 3192, 3160, 3036, 1759, 1627, 1606, 1515, 1473,
1350, 1329, 1303, 1281, 1257, 1214, 1119, 1097, 1071, 1023, 1008,
969, 931, 884, 859, 827, 811, 752, 716, 689, 663, 627, 503, 484 cm–1; 1H NMR (400 MHz, DMSO-d6): δ 10.93 (1H, s), 7.68 (2H, d, J = 8.0 Hz), 7.58 (1H, d, J = 7.2 Hz), 7.47 (1H,
t, J = 7.6 Hz), 7.36 (2H, d, J =
8.0 Hz), 7.13–7.09 (1H, m), 6.97 (1H, d, J = 8.0 Hz), 2.38 (3H, s); 13C NMR (100 MHz, DMSO-d6): δ 170.41, 159.34, 143.72, 143.17,
134.03, 130.28, 127.15, 126.51, 123.72, 121.33, 118.98, 111.88, 106.26,
21.62; HRMS (ESI+) m/z: calcd for C16H12N2O3Na [M + Na]+ 303.0740; found 303.0836.

9a-Hydroxy-3-(3-tolyl)-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (3f)
Yellow
solid; 75% yield; mp = 197.8–198.8 °C; IR (KBr) νmax: 3446, 3220, 3058, 1750, 1627, 1607, 1588, 1476, 1358,
1336, 1282, 1256, 1215, 1158, 1118, 1071, 1030, 967, 941, 884, 813,
787, 748, 688, 665, 618, 488 cm–1; 1H
NMR (600 MHz, DMSO-d6): δ 10.94
(1H, s), 7.63–7.59 (3H, m), 7.50–7.45 (3H, m), 7.13
(1H, t, J = 5.0 Hz), 6.97 (1H, d, J = 7.8 Hz), 2.37 (3H, s); 13C NMR (150 MHz, DMSO-d6): δ 170.41, 159.41, 143.77, 139.36,
134.10, 133.60, 129.68, 127.57, 126.56, 124.40, 123.76, 121.78, 121.34,
111.94, 106.39, 21.22; HRMS (ESI+) m/z: calcd for C16H12N2O3Na [M + Na]+ 303.0740; found 303.0742.

9a-Hydroxy-3-(2-tolyl)-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (3g)
Yellow
solid; 79% yield; mp = 170.5–173.1 °C; IR (KBr) νmax: 3318, 2980, 2922, 2276, 1752, 1734, 1625, 1494, 1471,
1395, 1325, 1274, 1248, 1210, 1121, 1078, 1064, 1019, 968, 932, 882,
855, 843, 818, 759, 749, 717, 690, 661, 620, 486, 442 cm–1; 1H NMR (400 MHz, DMSO-d6): δ 10.93 (1H, s), 7.71 (1H, d, J = 8.0 Hz),
7.61 (1H, d, J = 7.6 Hz), 7.53–7.42 (3H, m),
7.38–7.35 (1H, m), 7.12 (1H, t, J = 7.6 Hz),
6.78 (1H, d, J = 8.0 Hz), 2.54 (3H, s); 13C NMR (100 MHz, DMSO-d6): δ 170.49,
159.46, 143.75, 138.61, 133.99, 132.35, 132.00, 129.22, 126.84, 126.48,
123.73, 121.41, 120.99, 111.90, 105.47, 22.07; HRMS (ESI+) m/z: calcd for C17H13NO3Na [M + Na]+ 303.0740; found
303.0860.

3-(4-Ethylphenyl)-9a-hydroxy-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (3h)
White
solid; 76% yield; mp = 172.0–173.1 °C; IR (KBr) νmax: 3443, 3178, 2966, 2934, 2874, 1736, 1623, 1510, 1471,
1417, 1346, 1313, 1278, 1249, 1209, 1122, 1089, 1074, 1008, 971, 926,
843, 814, 757, 727, 686, 662, 647, 627, 534, 486; 1H NMR
(400 MHz, DMSO-d6): δ 10.95 (1H,
s), 7.72 (2H, d, J = 8.4 Hz), 7.58 (1H, d, J = 7.6 Hz), 7.49 (1H, t, J = 7.6 Hz),
7.42–7.40 (2H, m), 7.12 (1H, t, J = 7.6 Hz),
6.99 (1H, d, J = 8.0 Hz); 13C NMR (100
MHz, DMSO-d6): δ 170.41, 159.33,
149.27, 143.72, 134.03, 129.13, 127.27, 126.49, 123.72, 121.36, 119.23,
111.89, 106.27, 28.64, 15.64; HRMS (ESI+) m/z: calcd for C17H14N2O3Na [M + Na]+ 317.0897; found 317.0896.

3-(3-Fluorophenyl)-9a-hydroxy-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (3i)
Yellow
solid; 88% yield; mp = 201.0–202.5 °C; IR (KBr)
νmax: 3459, 3229, 2273, 1745, 1622, 1585, 1474, 1454,
1408, 1339, 1307, 1280, 1251, 1214, 1158, 1117, 1093, 1071, 1023,
969, 950, 873, 839, 811, 788, 755, 687, 653, 621, 523, 487, 455, 443; 1H NMR (400 MHz, DMSO-d6): δ
10.97 (1H, s), 7.67–7.58 (4H, m), 7.53–7.46 (2H, m),
7.12 (1H, t, J = 7.6 Hz), 6.98 (1H, d, J = 8.0 Hz); 13C NMR (100 MHz, DMSO-d6): δ 170.16, 163.72, 161.28, 158.56, 158.53, 143.79,
138.80, 134.19, 132.22, 132.14, 126.67, 125.12, 123.87, 123.78, 123.75,
123.48, 123.46, 123.20, 121.00, 120.09, 119.88, 114.08, 113.83, 112.65,
111.94, 106.79; HRMS (ESI+) m/z: calcd for C15H9FN2O3Na [M + Na]+ 307.0489; found 307.0490.

3-(2-Fluorophenyl)-9a-hydroxy-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (3j)
Yellow solid; 86% yield; mp = 180.5–182.3 °C; IR (KBr)
νmax: 3416, 3105, 1735, 1623, 1497, 1471, 1411, 1339,
1314, 1284, 1254, 1226, 1164, 1117, 1075, 1018, 974, 929, 849, 822,
767, 753, 728, 688, 661, 622, 551, 485, 418; 1H NMR (400
MHz, DMSO-d6): δ 10.96 (1H, s),
7.83–7.79 (1H, m), 7.73–7.69 (1H, m), 7.63 (1H, d, J = 7.2 Hz), 7.51–7.47 (2H, m), 7.40 (1H, t, J = 7.6 Hz), 7.15–7.11 (1H, m), 6.99 (1H, d, J = 7.6 Hz); 13C NMR (100 MHz, DMSO-d6): δ 170.21, 161.28, 158.72, 156.13, 156.07, 143.79,
135.16, 135.08, 134.17, 129.96, 126.65, 125.78, 125.74, 123.78, 121.05,
117.54, 117.34, 111.95, 110.14, 110.02, 105.80; HRMS (ESI+) m/z: calcd for C15H9FN2O3Na [M + Na]+ 307.0489;
found 307.0488.

3-(4-Chlorophenyl)-9a-hydroxy-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (3k)
Yellow solid; 85% yield; mp = 234.2–236.3 °C; IR (KBr)
νmax: 3451, 3217, 1745, 1653, 1626, 1597, 1493, 1474,
1405, 1347, 1282, 1253, 1210, 1157, 1120, 1095, 1068, 1023, 1009,
970, 838, 813, 759, 743, 714, 688, 660, 644, 620, 486 cm–1; 1H NMR (400 MHz, DMSO-d6): δ 10.96 (1H, s), 7.81 (2H, d, J = 8.0 Hz),
7.62 (3H, t, J = 8.4 Hz), 7.48 (1H, t, J = 7.6 Hz), 7.12 (1H, t, J = 7.2 Hz), 6.98 (1H,
d, J = 8.0 Hz); 13C NMR (100 MHz, DMSO-d6): δ 170.21, 158.69, 143.77, 137.67,
134.16, 129.96, 128.97, 126.64, 123.75, 121.04, 120.67, 111.93, 106.69;
HRMS (ESI+) m/z: calcd
for C15H9ClN2O3Na [M +
Na]+ 323.0194; found 323.0324.

3-(3-Chlorophenyl)-9a-hydroxy-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (3l)
White solid; 83% yield; mp = 262.5–263.5 °C; IR (KBr)
νmax: 3453, 3190, 3120, 1746, 1623, 1569, 1474, 1433,
1408, 1333, 1281, 1252, 1214, 1159, 1120, 1076, 1020, 969, 934, 888,
861, 813, 782, 768, 749, 682, 621, 493, 428; 1H NMR (400
MHz, DMSO-d6): δ 10.98 (1H, s),
7.80–7.78 (2H, m), 7.74–7.72 (1H, m), 7.64–7.59
(2H, m), 7.52–7.48 (1H, m), 6.99 (1H, t, J = 7.6 Hz), 6.99 (1H, d, J = 7.6 Hz); 13C NMR (100 MHz, DMSO-d6): δ 170.12,
158.38, 143.79, 134.44, 134.21, 132.83, 126.70, 126.64, 125.87, 123.75,
120.97, 111.94, 106.81; HRMS (ESI+) m/z: calcd for C15H9ClN2O3Na [M + Na]+ 323.0194; found 323.0194.

3-(2-Chlorophenyl)-9a-hydroxy-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (3m)
Yellow solid; 89% yield; mp = 173.1–174.1 °C; IR (KBr)
νmax: 3417, 3223, 3117, 1744, 1621, 1483, 1469, 1433,
1406, 1332, 1271, 1247, 1203, 1166, 1155, 1120, 1079, 1053, 1013,
971, 933, 869, 842, 812, 771, 757, 731, 689, 663, 650, 615, 519, 487; 1H NMR (400 MHz, DMSO-d6): δ
10.98 (1H, s), 7.86 (1H, d, J = 1.2 Hz), 7.84–7.64
(3H, m), 7.57–7.48 (2H, m), 7.15 (1H, t, J = 7.6 Hz), 7.00 (1H, d, J = 8.0 Hz); 13C NMR (100 MHz, DMSO-d6): δ 170.12,
157.68, 143.72, 134.13, 134.07, 132.70, 131.65, 131.46, 128.31, 126.55,
123.78, 121.18, 120.86, 111.95, 106.14; HRMS (ESI+) m/z: calcd for C15H9ClN2O3Na [M + Na]+ 323.0194; found
323.0193.

3-(4-Bromophenyl)-9a-hydroxy-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (3n)
Yellow
solid; 82% yield; mp = 262.5–263.5 °C; IR (KBr) νmax: 3443, 3215, 1737, 1627, 1592, 1488, 1473, 1400, 1344,
1309, 1284, 1254, 1213, 1180, 1117, 1090, 1067, 1018, 1005, 969, 855,
828, 811, 751, 721, 708, 686, 641, 617, 485, 472; 1H NMR
(400 MHz, DMSO-d6): δ 10.97 (1H,
s), 7.80–7.73 (4H, m), 7.62 (1H, d, J = 7.2
Hz), 7.51–7.47 (1H, m), 7.13 (1H, t, J = 7.6
Hz), 6.99 (1H, d, J = 7.6 Hz); 13C NMR
(100 MHz, DMSO-d6): δ 170.20, 158.81,
143.76, 134.18, 132.90, 129.08, 126.66, 126.58, 123.76, 121.02, 111.94,
106.70; HRMS (ESI+) m/z: calcd for C15H9BrN2O3Na [M + Na]+ 366.9689; found 366.9688.

9a-Hydroxy-3-(thiophen-3-yl)-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (3o)
Yellow
solid; 64% yield; mp = 166.8–168.7 °C; IR (KBr) νmax: 3445, 3219, 3116, 1737, 1625, 1518, 1471, 1435, 1331,
1298, 1280, 1252, 1209, 1156, 1116, 1087, 1071, 1026, 973, 936, 842,
813, 792, 757, 675, 617, 484, 419 cm–1; 1H NMR (600 MHz, DMSO-d6): δ 8.24
(1H, s), 7.81–7.76 (1H, m), 7.72–7.58 (1H, m), 7.49–7.47
(2H, m), 7.13–7.11 (1H, m), 6.97 (1H, d, J = 7.8 Hz); 13C NMR (150 MHz, DMSO-d6): δ 170.37, 156.36, 143.76, 134.08, 130.47, 129.65,
126.55, 125.74, 123.74, 122.32, 121.22, 111.91, 106.08; HRMS (ESI+) m/z: calcd for C13H8N2O3SNa [M + Na]+ 295.0148;
found 295.0151.

7-Fluoro-9a-hydroxy-3-phenyl-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (3p)
Yellow
solid; 72% yield; mp = 234.3–236.1 °C; IR (KBr) νmax: 3478, 3203, 3070, 1750, 1628, 1577, 1496, 1481, 1448,
1352, 1282, 1256, 1217, 1185, 1120, 1106, 1093, 1060, 1028, 1013,
944, 899, 859, 818, 798, 770, 748, 704, 685, 655, 633, 592, 499, 468
cm–1; 1H NMR (400 MHz, DMSO-d6): δ 11.00 (1H, s), 7.83–7.80 (2H, m), 7.68–7.64
(2H, m), 7.60–7.56 (2H, m), 7.38–7.33 (1H, m), 7.02–6.98
(1H, m); 13C NMR (100 MHz, DMSO-d6): δ 170.46, 160.15, 159.24, 157.76, 139.94, 139.92,
132.98, 129.74, 127.25, 122.72, 122.64, 121.74, 120.75, 120.52, 114.56,
114.31, 113.20, 113.12, 106.22; HRMS (ESI+) m/z: calcd for C15H9FN2O3Na [M + Na]+ 307.0489; found 307.0491.

7-Fluoro-9a-hydroxy-3-(4-tolyl)-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (3q)
Yellow
solid; 69% yield; mp = 233.0–234.5 °C; IR (KBr)
νmax: 3447, 3198, 3072, 1753, 1630, 1612, 1496, 1483,
1409, 1352, 1309, 1281, 1257, 1217, 1184, 1119, 1100, 1059, 1024,
1011, 945, 901, 860, 817, 799, 749, 702, 655, 635, 614, 592, 487 cm–1; 1H NMR (400 MHz, DMSO-d6): δ 10.97 (1H, s), 7.69 (2H, d, J = 8.4 Hz), 7.64–7.62 (1H, m), 7.39–7.32 (3H, m), 7.00–6.97
(1H, dd, J = 4, 8.8 Hz), 2.39 (3H, s); 13C NMR (100 MHz, DMSO-d6): δ 170.51,
160.14, 159.28, 157.75, 143.20, 139.92, 139.90, 130.25, 127.21, 122.79,
122.71, 120.69, 120.46, 118.89, 114.48, 114.23, 113.17, 113.09, 106.05,
21.62; HRMS (ESI+) m/z: calcd for C16H11FN2O3Na [M + Na]+ 321.0646; found 321.0649.

7-Fluoro-9a-hydroxy-3-(4-methoxyphenyl)-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (3r)
Yellow solid; 70% yield; mp = 253.5–254.7 °C; IR (KBr)
νmax: 3551, 3477, 3234, 1741, 1635, 1616, 1515, 1481,
1424, 1352, 1311, 1260, 1207, 1174, 1119, 1093, 1059, 1022, 1004,
930, 903, 827, 799, 704, 618, 592, 478 cm–1; 1H NMR (500 MHz, DMSO-d6): δ
10.95 (1H, s), 7.74 (2H, d, J = 9.0 Hz), 7.63–7.61
(1H, dd, J = 2.5, 7.5 Hz), 7.36–7.32 (1H,
m), 7.11 (2H, d, J = 9.0 Hz), 7.00–6.97 (1H,
dd, J = 4, 8.5 Hz), 3.85 (3H, s); 13C
NMR (125 MHz, DMSO-d6): δ 170.60,
162.84, 159.91, 159.11, 158.00, 139.91, 129.17, 122.87, 122.81, 120.63,
120.44, 115.20, 114.41, 114.21, 113.77, 113.15, 113.09, 105.90, 56.00;
HRMS (ESI+) m/z: calcd
for C16H11FN2O4Na [M +
Na]+ 337.0595; found 337.0597.

7-Fluoro-3-(4-fluorophenyl)-9a-hydroxy-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (3s)
Yellow solid; 87% yield; mp = 193.4–195.2 °C; IR (KBr)
νmax: 3449, 3207, 3071, 1747, 1633, 1603, 1511, 1492,
1413, 1349, 1279, 1211, 1184, 1157, 1115, 1088, 1061, 1020, 1009,
947, 930, 910, 877, 847, 816, 798, 747, 729, 703, 653, 614, 591, 512,
489, 420 cm–1; 1H NMR (400 MHz, DMSO-d6): δ 10.99 (1H, s), 7.90–7.86
(2H, m), 7.68–7.65 (1H, m), 7.43 (2H, t, J = 8.8 Hz), 7.37–7.32 (1H, m), 7.01–6.98 (1H, dd, J = 4.0, 8.8 Hz); 13C NMR (100 MHz, DMSO-d6): δ 170.38, 166.04, 163.55, 160.15,
158.56, 157.76, 139.94, 130.06, 129.97, 122.61, 122.53, 120.79, 120.55,
118.34, 118.31, 117.17, 116.95, 114.60, 114.35, 113.20, 113.12, 106.33;
HRMS (ESI+) m/z: calcd
for C15H8F2N2O3Na [M + Na]+ 325.0395; found 325.0393.

9a-Hydroxy-7-methoxy-3-phenyl-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (3t)
Red solid; 87% yield; mp = 159.1–161.9 °C; IR (KBr)
νmax: 3250, 3056, 2957, 2938, 2835, 1746, 1633, 1613,
1578, 1493, 1450, 1440, 1354, 1301, 1276, 1251, 1213, 1178, 1130,
1094, 1079, 1030, 1013, 993, 917, 901, 877, 860, 805, 767, 745, 727,
703, 688, 655, 606, 523, 496, 457 cm–1; 1H NMR (400 MHz, DMSO-d6): δ 10.75
(1H, s), 7.81 (2H, d, J = 7.2 Hz), 7.66–7.63
(1H, m), 7.57 (2H, t, J = 7.6 Hz), 7.27 (1H, d, J = 3.6 Hz), 7.06–7.03 (1H, m), 6.90 (1H, d, J = 7.6 Hz), 3.73 (3H, s); 13C NMR (100 MHz,
DMSO-d6): δ 170.49, 159.27, 156.31,
136.76, 132.89, 129.72, 127.21, 122.13, 121.91, 119.75, 112.71, 112.24,
106.77, 56.25; HRMS (ESI+) m/z: calcd for C16H12N2O4Na [M + Na]+ 319.0689; found 319.0715.

9a-Hydroxy-7-methoxy-3-(4-tolyl)-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (3u)
Red solid; 84% yield; mp = 195.5–198.4 °C; IR (KBr)
νmax: 3296, 1753, 1630, 1613, 1560, 1495, 1443, 1410,
1345, 1303, 1279, 1205, 1177, 1142, 1089, 1073, 1026, 1011, 989, 932,
883, 856, 823, 774, 743, 726, 703, 652, 637, 612, 491 cm–1; 1H NMR (400 MHz, DMSO-d6): δ 10.73 (1H, s), 7.69 (2H, d, J = 8.4 Hz),
7.37 (2H, d, J = 8.0 Hz), 7.25 (1H, d, J = 2.4 Hz), 7.05–7.03 (1H, dd, J = 8.8, 2.8
Hz), 6.90 (1H, d, J = 8.8 Hz), 3.73 (3H, s), 2.38
(3H, s); 13C NMR (100 MHz, DMSO-d6): δ 170.54, 159.31, 156.29, 143.10, 136.74, 130.24,
127.17, 122.21, 119.66, 119.07, 112.68, 112.17, 106.59, 56.23, 21.61;
HRMS (ESI+) m/z: calcd
for C17H14N2O4Na [M +
Na]+ 333.0846; found 333.0902.

9a-Hydroxy-7-methoxy-3-(2-tolyl)-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (3v)
Red solid; 78% yield; mp = 161.2–163.4 °C; IR (KBr)
νmax: 3428, 3194, 3105, 2972, 2935, 1735, 1617, 1495,
1470, 1437, 1381, 1328, 1304, 1283, 1215, 1173, 1139, 1127, 1074,
1030, 1016, 933, 901, 881, 849, 821, 786, 763, 730, 712, 657, 585,
523, 502, 441 cm–1; 1H NMR (400 MHz,
DMSO-d6): δ 10.73 (1H, s), 7.72
(1H, d, J = 7.6 Hz), 7.53–7.50 (1H, m), 7.43
(1H, d, J = 7.6 Hz), 7.37 (1H, t, J = 7.6 Hz), 7.28 (1H, d, J = 2.8 Hz), 7.06–7.03
(1H, m), 6.90 (1H, d, J = 8.4 Hz), 3.74 (3H, s),
2.54 (3H, s); 13C NMR (100 MHz, DMSO-d6): δ 170.62, 159.42, 156.31, 138.62, 136.77, 132.31,
131.97, 129.26, 126.80, 122.30, 121.06, 119.58, 112.69, 112.22, 105.77,
56.25, 22.11; HRMS (ESI+) m/z: calcd for C17H14N2O4Na [M + Na]+ 333.0846; found 333.0984.

3-(4-Fluorophenyl)-9a-hydroxy-7-methoxy-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (3w)
Red solid; 96% yield; mp = 196.5–198.4 °C; IR (KBr)
νmax: 3289, 2928, 2844, 1752, 1633, 1606, 1561, 1511,
1495, 1442, 1413, 1348, 1302, 1279, 1208, 1178, 1158, 1091, 1071,
1025, 883, 841, 812, 775, 744, 727, 703, 650, 635, 614, 513, 486 cm–1; 1H NMR (400 MHz, DMSO-d6): δ 10.75 (1H, s), 7.89–7.85 (2H, m), 7.43–7.39
(2H, m), 7.27 (1H, d, J = 2.4 Hz), 7.06–7.03
(1H, m), 6.90 (1H, d, J = 8.4 Hz), 3.74 (3H, d, J = 5.6); 13C NMR (100 MHz, DMSO-d6): δ 170.41, 166.00, 163.50, 158.60, 156.30, 136.77,
130.00, 129.91, 122.01, 119.76, 118.51, 117.14, 116.91, 112.70, 112.28,
106.88, 56.23; HRMS (ESI+) m/z: calcd for C16H11FN2O4Na [M + Na]+ 337.0595; found 337.0642.

3-(2-Fluorophenyl)-9a-hydroxy-7-methoxy-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (3x)
Red solid; 85% yield; mp = 160.5–161.0 °C; IR (KBr)
νmax: 3418, 1735, 1619, 1496, 1439, 1340, 1304, 1228,
1180, 1125, 1074, 1028, 821, 764, 659, 586; 1H NMR (400
MHz, DMSO-d6): δ 10.76 (1H, s),
7.83–7.79 (1H, m), 7.74–7.69 (1H, m), 7.51–7.46
(1H, m), 7.43–7.39 (1H, m), 7.31 (1H, d, J = 2.8 Hz), 7.07–7.04 (1H, m), 6.91 (1H, d, J = 8.8 Hz), 3.74 (3H, s); 13C NMR (100 MHz, DMSO-d6): δ 170.35, 161.28, 158.72, 156.32,
156.08, 156.01, 136.79, 135.07, 134.99, 129.98, 125.72, 125.69, 121.96,
119.80, 117.50, 117.29, 112.74, 112.32, 110.26, 110.14, 106.10, 56.26;
HRMS (ESI+) m/z: calcd
for C16H11FN2O4Na [M +
Na]+ 337.0595; found 337.0597.

9a-Hydroxy-7-methyl-3-phenyl-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (3y)
Yellow
solid; 85% yield; mp = 153.8–155.4 °C; IR (KBr) νmax: 3195, 3106, 1734, 1628, 1575, 1493, 1451, 1409, 1351,
1294, 1251, 1212, 1178, 1130, 1089, 1064, 1031, 1015, 943, 927, 891,
847, 819, 771, 703, 686, 654, 590, 578, 490, 460, 434 cm–1; 1H NMR (400 MHz, DMSO-d6): δ 10.85 (1H, s), 7.80 (2H, d, J = 7.6 Hz),
7.64 (1H, t, J = 7.6 Hz), 7.56 (2H, t, J = 15.2 Hz), 7.42 (1H, s), 7.27 (1H, d, J = 8.0
Hz), 6.87 (1H, d, J = 8.0 Hz); 13C NMR
(100 MHz, DMSO-d6): δ 170.37, 159.24,
141.18, 134.24, 133.08, 132.92, 129.75, 127.16, 126.89, 121.85, 121.34,
111.65, 106.64, 20.74; HRMS (ESI+) m/z: calcd for C16H12N2O3Na [M + Na]+ 303.0740; found 303.0730.

9a-Hydroxy-7-methyl-3-(4-tolyl)-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (3z)
Yellow solid; 82% yield; mp = 188.7–190.8 °C; IR (KBr)
νmax: 3201, 3036, 2921, 1748, 1628, 1500, 1410, 1355,
1295, 1259, 1219, 1184, 1132, 1101, 1065, 1010, 944, 908, 861, 820,
752, 709, 655, 636, 589, 489, 457 cm–1; 1H NMR (400 MHz, DMSO-d6): δ 10.84
(1H, s), 7.68 (2H, d, J = 8.0 Hz), 7.39–7.34
(3H, m), 7.26 (1H, d, J = 8.0 Hz), 6.86 (1H, d, J = 8.0 Hz), 2.37 (3H, s), 2.25 (3H, s); 13C
NMR (100 MHz, DMSO-d6): δ 170.45,
159.29, 143.10, 141.17, 134.16, 133.02, 130.24, 127.11, 126.79, 121.44,
119.03, 111.62, 106.47, 21.59, 20.73; HRMS (ESI+) m/z: calcd for C17H14N2O3Na [M + Na]+ 317.0897; found
317.0962.

9a-Hydroxy-7-methyl-3-(2-tolyl)-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (4a)
Yellow solid; 81% yield; mp = 138.1–141.7 °C; IR (KBr)
νmax: 3197, 3115, 2971, 2923, 1751, 1632, 1617, 1494,
1454, 1410, 1333, 1295, 1281, 1251, 1215, 1187, 1137, 1077, 1016,
951, 933, 880, 853, 822, 805, 759, 718, 703, 656, 592, 502, 461, 445
cm–1; 1H NMR (400 MHz, DMSO-d6): δ 10.82 (1H, s), 7.70 (1H, d, J = 7.6 Hz), 7.51 (1H, d, J = 7.2 Hz), 7.43 (2H,
d, J = 7.2 Hz), 7.36 (1H, t, J =
7.6 Hz), 7.27 (1H, d, J = 8.0 Hz), 6.87 (1H, d, J = 8.0 Hz), 2.54 (3H, s), 2.26 (3H, s); 13C
NMR (100 MHz, DMSO-d6): δ 170.52,
159.39, 141.20, 138.59, 134.14, 133.05, 132.32, 131.99, 129.19, 126.82,
121.48, 121.01, 111.63, 105.64, 22.11, 20.76; HRMS (ESI+) m/z: calcd for C17H14N2O3Na [M + Na]+ 317.0897;
found 317.0955.

3-(4-Fluorophenyl)-9a-hydroxy-7-methyl-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (4b)
Red solid; 92% yield; mp = 204.7–206.9 °C; IR (KBr)
νmax: 3231, 2923, 1752, 1685, 1631, 1606, 1512, 1499,
1414, 1357, 1293, 1255, 1238, 1219, 1183, 1158, 1130, 1112, 1098,
1069, 1016, 941, 905.45, 864, 816, 750, 732, 719, 703, 652, 637, 615,
590, 508, 495 cm–1; 1H NMR (400 MHz,
DMSO-d6): δ 10.85 (1H, s), 7.88–7.85
(2H, m), 7.43–7.38 (3H, m), 7.27 (1H, d, J = 7.6 Hz), 6.86 (1H, d, J = 8.0 Hz), 2.25 (3H,
m); 13C NMR (100 MHz, DMSO-d6): δ 170.29, 166.01, 163.52, 158.56, 141.19, 134.27, 133.07,
129.96, 129.87, 126.92, 121.21, 118.43, 117.17, 116.95, 111.65, 106.75,
20.73; HRMS (ESI+) m/z: calcd for C16H11FN2O3Na [M + Na]+ 321.0646; found 321.0769.

3-(3-Fluorophenyl)-9a-hydroxy-7-methyl-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (4c)
Red solid; 89% yield; mp = 166.5–168.7 °C; IR (KBr)
νmax: 3418, 1747, 1627, 1587, 1496, 1452, 1405, 1338,
1291, 1253, 1220, 1182, 1136, 1094, 1068, 1022, 943, 875, 840, 815,
781, 760, 703, 682, 593, 461; 1H NMR (400 MHz, DMSO-d6): δ 10.86 (1H, s), 7.67–7.61
(3H, m), 7.59–7.53 (1H, m), 7.45 (1H, s), 7.30–7.28
(1H, dd, J = 0.8, 8.0 Hz), 6.87 (1H, d, J = 8.0 Hz), 2.27 (3H, s); 13C NMR (100 MHz, DMSO-d6): δ 170.15, 163.72, 161.28, 158.49,
158.45, 141.20, 134.37, 133.12, 132.26, 132.17, 127.01, 123.88, 123.80,
123.49, 123.46, 121.07, 120.10, 119.89, 114.07, 113.82, 111.69, 106.97,
20.75; HRMS (ESI+) m/z: calcd for C16H11FN2O3Na [M + Na]+ 321.0646; found 321.0647.

3-(2-Fluorophenyl)-9a-hydroxy-7-methyl-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (4d)
Yellow solid; 88% yield; mp = 192.3–193.5 °C; IR (KBr)
νmax: 3419, 1738, 1627, 1493, 1463, 1409, 1354, 1341,
1294, 1252, 1215, 1185, 1164, 1119, 1075, 1035, 1016, 929, 895, 824,
768, 702, 653, 591, 550, 455; 1H NMR (400 MHz, DMSO-d6): δ 10.86 (1H, s), 7.82–7.78
(1H, m), 7.72–7.70 (1H, m), 7.50–7.45 (2H, m), 7.42–7.38
(1H, m), 7.28 (1H, d, J = 8.0 Hz), 6.87 (1H, d, J = 8.0 Hz), 2.27 (3H, s); 13C NMR (100 MHz,
DMSO-d6): δ 170.24, 161.27, 158.71,
156.06, 156.00, 141.22, 135.11, 135.02, 134.31, 133.11, 129.92, 126.95,
125.75, 125.71, 121.13, 117.52, 117.32, 111.68, 110.17, 110.05, 105.99,
20.75; HRMS (ESI+) m/z: calcd for C16H11FN2O3Na [M + Na]+ 321.0646; found 321.0648.

3-(4-Chlorophenyl)-9a-hydroxy-7-methyl-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (4e)
Yellow solid; 80% yield; mp = 226.3–227.4 °C; IR (KBr)
νmax: 3199, 2922, 1754, 1629, 1598, 1495, 1405, 1349,
1292, 1255, 1216, 1181, 1130, 1100, 1067, 1008, 940, 904, 834, 813,
787, 754, 731, 714, 702, 652, 636, 590, 526, 491 cm–1; 1H NMR (400 MHz, DMSO-d6): δ 10.85 (1H, s), 7.81 (2H, d, J = 8.4 Hz),
7.63 (2H, d, J = 8.4 Hz), 7.43 (1H, s), 7.27 (1H,
d, J = 8.0 Hz), 6.86 (1H, d, J =
8.0 Hz), 2.25 (3H, s); 13C NMR (100 MHz, DMSO-d6): δ 170.22, 158.62, 141.20, 137.64, 134.32, 133.09,
129.95, 128.95, 126.95, 121.12, 120.70, 111.67, 106.89, 20.74; HRMS
(ESI+) m/z: calcd for
C16H11ClN2O3Na [M + Na]+ 337.0350; found 337.0470.

7-Bromo-9a-hydroxy-3-phenyl-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (4f)
Yellow
solid; 83% yield; mp = 194.1–196.2 °C; IR (KBr) νmax: 3187, 3145, 3114, 3060, 2857, 1745, 1618, 1575, 1496,
1475, 1447, 1350, 1312, 1210, 1134, 1094, 1072, 1050, 1029, 1014,
932, 878, 858, 814, 766, 730, 692, 649, 570, 533, 485, 456 cm–1; 1H NMR (400 MHz, DMSO-d6): δ 11.10 (1H, s), 7.91 (1H, d, J = 2 Hz), 7.80 (2H, d, J = 7.2 Hz), 7.67–7.63
(2H, m), 7.56 (2H, t, J = 7.6 Hz), 6.94 (1H, d, J = 8.4 Hz); 13C NMR (100 MHz, DMSO-d6): δ 169.99, 159.24, 143.00, 136.69, 132.95, 129.70,
129.51, 127.27, 123.53, 121.75, 115.21, 113.97, 105.94; HRMS (ESI+) m/z: calcd for C15H9BrN2O3Na [M + Na]+ 366.9689;
found 366.9814.

7-Bromo-9a-hydroxy-3-(4-tolyl)-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (4g)
Yellow solid; 81% yield; mp = 210.7–213.1 °C; IR (KBr)
νmax: 3221, 3190, 3060, 2921, 1755, 1627, 1513, 1473,
1446, 1409, 1351, 1308, 1266, 1208, 1130, 1101, 1079, 1051, 1025,
1011, 940, 909, 888, 862, 819, 748, 731, 702, 689, 653, 630, 535,
492 cm–1; 1H NMR (400 MHz, DMSO-d6): δ 11.08 (1H, s), 7.87 (1H, s), 7.69–7.64
(3H, m), 7.37 (2H, d, J = 8.0 Hz), 6.94 (1H, d, J = 8.4 Hz), 2.38 (3H, s); 13C NMR (100 MHz,
DMSO-d6): δ 170.04, 159.28, 143.18,
142.99, 136.64, 130.23, 129.42, 127.23, 123.60, 118.90, 115.18, 113.95,
105.76, 21.63; HRMS (ESI+) m/z: calcd for C16H11BrN2O3Na [M + Na]+ 380.9845; found 380.9776.

7-Bromo-9a-hydroxy-3-(2-tolyl)-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (4h)
Red solid; 82% yield; mp = 138.4–140.4 °C; IR (KBr)
νmax: 3197, 3113, 2975, 2922, 2847, 1763, 1619, 1498,
1476, 1440, 1398, 1330, 1265, 1247, 1211, 1134, 1087, 1069, 1052,
1019, 954, 933, 884, 852, 822, 807, 762, 719, 704, 689, 665, 653,
572, 535, 506, 457, 446 cm–1; 1H NMR
(400 MHz, DMSO-d6): δ 11.08 (1H,
s), 7.92 (1H, s), 7.92–7.65 (2H, m), 7.52 (1H, t, J = 7.6 Hz), 7.43 (1H, d, J = 7.6 Hz), 7.36 (1H,
t, J = 7.6 Hz), 6.94 (1H, d, J =
8.4 Hz), 2.53 (3H, s); 13C NMR (100 MHz, DMSO-d6): δ 170.15, 159.33, 143.01, 138.69, 136.60, 132.36,
131.94, 129.42, 129.29, 126.77, 123.70, 120.90, 115.20, 113.96, 104.95;
HRMS (ESI+) m/z: calcd
for C16H11BrN2O3Na [M
+ Na]+ 380.9845; found 380.9933.

7-Bromo-3-(4-fluorophenyl)-9a-hydroxy-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (4i)
Yellow solid; 87% yield; mp = 232.5–233.3 °C; IR (KBr)
νmax: 3220, 3191, 3060, 1758, 1629, 1605, 1512, 1472,
1447, 1414, 1353, 1295, 1266, 1210, 1158, 1131, 1111, 1099, 1081,
1052, 1020, 939, 910, 888, 862, 840, 818, 748, 719, 690 cm–1; 1H NMR (400 MHz, DMSO-d6): δ 11.10 (1H, s), 7.91–7.85 (3H, m), 7.67–7.64
(1H, m), 7.43–7.39 (2H, m), 6.94 (1H, d, J = 8.4 Hz); 13C NMR (100 MHz, DMSO-d6): δ 169.92, 166.02, 163.53, 158.56, 143.00, 136.70,
130.07, 129.98, 129.55, 123.43, 118.36, 117.12, 116.90, 115.21, 113.96,
106.05; HRMS (ESI+) m/z: calcd for C15H8BrFN2O3Na [M + Na]+ 384.9595; found 384.9671.

7-Bromo-3-(4-chlorophenyl)-9a-hydroxy-[1,2,4]oxadiazolo[4,5-a]indol-9(9aH)-one (4j)
Yellow solid; 85% yield; mp = 229.6–231.2 °C; IR (KBr)
νmax: 3452, 1755, 1625, 1598, 1493, 1477, 1442, 1404,
1344, 1263, 1207, 1134, 1096, 1051, 1010, 883, 816, 757, 700, 647,
537 cm–1; 1H NMR (400 MHz, DMSO-d6): δ 11.11 (1H, s), 7.91 (1H, s), 7.80
(2H, d, J = 8.4 Hz), 7.66–7.60 (3H, m), 6.93
(1H, d, J = 8.4 Hz); 13C NMR (100 MHz,
DMSO-d6): δ 169.84, 158.62, 143.00,
137.66, 136.72, 129.87, 129.56, 129.03, 123.36, 120.62, 115.22, 113.96,
106.17; HRMS (ESI+) m/z: calcd for C15H8BrClN2O3Na [M + Na]+ 400.9299; found 400.9412.

3-Phenyl-4-(2-(3-phenyl-1,2,4-oxadiazol-5-yl)phenyl)-1,2,4-oxadiazol-5(4H)-one (6a)
White solid; 78% yield;
mp = 165.1–167.4 °C; 1H NMR (400 MHz, DMSO-d6): δ 8.32 (1H, d, J =
6.8 Hz), 8.05–8.04 (3H, m), 7.98–7.94 (1H, m), 7.87–7.84
(1H, m), 7.65–7.63 (3H, m), 7.48 (1H, t, J = 7.6 Hz), 7.35 (2H, d, J = 8.0 Hz), 7.28 (2H,
d, J = 7.2 Hz); 13C NMR (100 MHz, DMSO-d6): δ 172.5, 168.6, 158.5, 158.1, 135.3,
132.5, 132.4, 132.1, 131.1, 130.6, 129.9, 129.7, 129.5, 129.0, 128.3,
127.4, 126.0, 123.1, 121.8; HRMS (ESI+) m/z: calcd for C22H14N4O3Na [M + Na]+ 405.0964; found 405.0953.

3-Phenyl-5H-[1,2,4]oxadiazolo[4,5-c]pyrimidine-5,7(6H)-dione (6b)
White solid; 86% yield; mp = 132.5–134.1 °C; 1H NMR (400 MHz, DMSO-d6): δ 11.55
(1H, s), 7.77–7.75 (2H, m), 7.67–7.63 (1H, m), 7.57–7.53
(2H, m), 5.59 (1H, s); 13C NMR (100 MHz, DMSO-d6): δ 164.07, 163.94, 154.56, 143.69, 132.39, 130.78,
128.47, 121.59, 73.74; HRMS (ESI+) m/z: calcd for C11H7N3O3Na [M + Na]+ 252.0385; found 252.0373.

6-Methyl-3-phenyl-5H-[1,2,4]oxadiazolo[4,5-c]pyrimidine-5,7(6H)-dione (6c)
White solid; 88% yield;
mp = 153.2–155.8 °C;
IR (KBr) νmax: 3416, 3109, 1728, 1703, 1674, 1659,
1563, 1491, 1439, 1360, 1342, 1263, 1233, 1185, 1136, 1040, 1001,
978, 893, 851, 833, 785, 765, 746, 709, 691, 677, 659, 621, 544, 475,
445, 408 cm–1; 1H NMR (600 MHz, DMSO-d6): δ 7.77 (2H, d, J =
7.2 Hz), 7.68–7.66 (1H, m), 7.57 (2H, t, J = 7.8 Hz), 5.80 (1H, s), 3.15 (3H, s); 13C NMR (150 MHz,
DMSO-d6): δ 162.57, 162.39, 154.62,
144.41, 132.42, 130.81, 128.49, 121.60, 73.33, 27.99; HRMS (ESI+) m/z: calcd for C12H10N3O3 [M + H]+ 244.0717;
found 262.0723.

6-Ethyl-7-imino-3-phenyl-7,8-dihydro-8aH-[1,2,4]oxadiazolo[4,5-a]pyrimidin-8a-ol
(6d)
White solid;
82% yield; mp = 131.1–132.9 °C; 1H NMR (400
MHz, CDCl3): δ 7.97–7.87 (2H, m), 7.64–7.53
(1H, m), 7.47 (3H, t, J = 7.3 Hz), 7.27 (2H, d, J = 13.2 Hz), 2.06 (3H, q, J = 7.4 Hz),
0.98 (4H, t, J = 7.4 Hz); 13C NMR (100
MHz, CDCl3): δ 154.26, 144.44, 130.63, 129.10, 127.56,
127.19, 126.33, 122.69, 117.31, 21.22, 14.67; HRMS (ESI+) m/z: calcd for C13H14N4O2Na [M + Na]+ 281.1014;
found 281.1003.

6-Nitro-3-phenylimidazo[1,2-d][1,2,4]oxadiazole
(6e)
White solid; 89% yield; mp = 187.2–189.5
°C; IR (KBr) νmax: 3416, 3148, 1999, 1636, 1604,
1584, 1533, 1484, 1452, 1354, 1306, 1291, 1278, 1154, 1132, 1073,
1028, 970, 880, 852, 790, 771, 753, 722, 686, 670, 644, 480, 456; 1H NMR (400 MHz, DMSO-d6): δ
9.28 (1H, s), 8.15–8.13 (2H, m), 7.77–7.75 (1H, m),
7.71–7.67 (2H, m); 13C NMR (100 MHz, DMSO-d6): δ 158.80, 152.59, 151.33, 133.86,
130.13, 127.96, 121.14, 110.43; HRMS (ESI+) m/z: calcd for C10H6N4O3Na [M + Na]+ 253.0332; found 253.0337.

General Computation Methods
All computations were carried
out with Gaussian 09. Reactants, transition stats, and products were
optimized with the density-functional M06-2X1 using the
6-31G(d) basis set with an ultrafine grid, consisting of 590 radial
shell and 99 grid points per shell.2 M06-2X
has been found to give reliable energetics for cycloadditions involving
main group elements.3 Normal vibrational
mode analysis confirmed all stationary points to be minima (no imaginary
frequencies) or transition states (one imaginary frequency). Zero-point
energy and thermal corrections were computed from unscaled frequencies
for the standard state of 1 M and 298.15 K. Truhlar’s quasiharmonic
correction was applied for entropy calculations by setting all frequencies
less than 100 cm–1.4 Input
structures for these computations were generated using GaussView.

General Procedure for Biological Activity
Cytotoxicity
of 3a and 3b was determined by the MTT assay
against three human ovarian cancer cell lines, NCI/ADR-RES, SKOV3,
and OVCAR8. All compounds were preliminary screened for their cytotoxic
activity at 10 μM. We also investigated the level of colony
formation to assess the effects of cytotoxicity on the NCI/ADR-RES
cancer cell growth at 10 μM.

Cell Lines
NCI/ADR-RES
is an ovarian cancer cell resistant
to doxorubicin.

SKOV3 and OVCAR8 are ovarian cancer cells.

MTT Assay
The evaluation of cytotoxicity was based
on the reduction of MTT dye by viable cells to give purple formazan
products, which can be measured spectrophotometrically at 540 nm.
One hundred eighty microliters of cancer cells were seeded into 96-well
plates at 2000 cell/well and incubated at 37 °C overnight before
the indicated treatments. After 72 h, 20 μL of the MTT solution
(3 mg/mL) was added and incubated again for 3 h. After removal of
the media and the solubilization of the formazan crystals in 150 μL
of DMSO, absorbance was measured at 570 nm. Percentage of cell growth
inhibition is expressed as 1 – [(A – B)/(C – B)] ×
100% (A, B, and C were the absorbance values from experimental, blank, and control
cells, respectively).

Colony Assay
Colony formation assay
is an in vitro
cell survival assay based on the ability of a single cell to grow
into a colony. This technique was also performed to confirm the activity.
Briefly, cells were plated in 96-well plates at a density of 200 cells/well
and allowed to attach overnight. The next day, the corresponding compounds
were added and allowed to incubate for 24 h. After exposure, cells
were changed with new media and cultured until colonies were formed
(7–10 days). Cells were subsequently washed and stained with
a solution of crystal violet for 30 min. After staining, the cells
were thoroughly washed with water. Colonies were imaged on the inverted
fluorescence microscope.

Supporting Information Available
The Supporting
Information is
available free of charge on the ACS Publications website at DOI: 10.1021/acsomega.7b00490.1H
NMR of isatin in different solvents, equilibrium
constants (Kn) of tautomerization,
Cartesian coordinates and energy, and 1H NMR and 13C NMR spectra (PDF)



Supplementary Material
ao7b00490_si_001.pdf

 The authors
declare no competing financial interest.

Acknowledgments
The authors gratefully acknowledge the financial
support of the Program for Changjiang Scholars and Innovative Research
Team in University (no. IRT13095) and the NSFC (nos. 21262043, 21662044,
20902079, U1202221, and 21262042) and thank the High Performance Computing
Center at Yunnan University for use of the high performance computing
platform.
==== Refs
References
a Ji Y. ; Yang X. ; Qian Y. 
RSC Adv. 
2014 , 4 , 49535 –49540 . 10.1039/c4ra09081k .b Taylor P. J.  The “Basicity
Method” for Estimating Tautomer Ratio: A Radical Re-Appraisal . In Tautomerism: Methods and Theories ; Wiley-VCH Verlag GmbH & Co. KGaA , 2013 ; Vol. 12 , pp 305 –335 .c Oszczapowicz J.  Basicity,
H-Bonding, Tautomerism and
Complex Formation of Imidic Acid Derivatives . In Amidines and Imidates ; John Wiley &
Sons, Ltd. , 1991 ; Vol. 2 , pp 623 –688 .d Buśko-Oszczapowicz I. ; Oszczapowicz J.  Detection
and Determination of Imidic Acid Derivatives . In Amidines and Imidates ; John Wiley &
Sons, Ltd. , 1991 ; Vol. 2 , pp 231 –299 .
Kemnitz C. R. ; Loewen M. J. 
J. Am. Chem. Soc. 
2007 , 129 , 2521 –2528 . 10.1021/ja0663024 .17295481 
a Wong M. W. ; Leung-Toung R. ; Wentrup C. 
J. Am. Chem. Soc. 
1993 , 115 , 2465 –2472 . 10.1021/ja00059a048 . b Balabin R. M. 
J. Chem. Phys. 
2009 , 131 , 154307 10.1063/1.3249968 .20568864 
Chandanshive J. Z. ; González P. B. ; Tiznado W. ; Bonini B. F. ; et al. Tetrahedron 
2012 , 68 , 3319 –3328 . 10.1016/j.tet.2012.02.068 .
a Ritter T. ; Carreira E. M. 
Angew. Chem., Int. Ed. 
2005 , 44 , 936 –938 . 10.1002/anie.200461934 . b Tang Y. ; Gao H. ; Mitchell L. A. ; Parrish D. A. ; et al. Angew. Chem., Int. Ed. 
2016 , 55 , 1147 –1150 . 10.1002/anie.201509985 .
Carbone M. ; Li Y. ; Irace C. ; Mollo E. ; et al. Org.
Lett. 
2011 , 13 , 2516 –2519 . 10.1021/ol200234r .21506595 
a Takahashi H. ; Riether D. ; Bartolozzi A. ; Bosanac T. ; et al. J. Med. Chem. 
2015 , 58 , 1669 –1690 . 10.1021/jm501185j .25671290  b Budriesi R. ; Cosimelli B. ; Ioan P. ; Ugenti M. P. ; et al. J. Med. Chem. 
2009 , 52 , 2352 –2362 . 10.1021/jm801351u .19323482  c Touaibia M. ; Djimdé A. ; Cao F. ; Boilard E. ; et al. J. Med. Chem. 
2007 , 50 , 1618 –1626 . 10.1021/jm060082n .17335183 
a Dickmeis M. ; Cinar H. ; Ritter H. 
Angew. Chem., Int. Ed. 
2012 , 51 , 3957 –3959 . 10.1002/anie.201107608 . b Koyama Y. ; Miura K. ; Cheawchan S. ; Seo A. ; et al. Chem. Commun. 
2012 , 48 , 10304 –10306 . 10.1039/c2cc35158g . c Li Q. ; Cui L.-S. ; Zhong C. ; Jiang Z.-Q. ; et al. Org. Lett. 
2014 , 16 , 1622 –1625 . 10.1021/ol5002494 .24588625  d Tang Y. ; Gao H. ; Mitchell L. A. ; Parrish D. A. ; et al. Angew. Chem., Int. Ed. 
2016 , 55 , 3200 –3203 . 10.1002/anie.201600068 . e Wei H. ; He C. ; Zhang J. ; Shreeve J. M. 
Angew. Chem., Int. Ed. 
2015 , 54 , 9367 –9371 . 10.1002/anie.201503532 .
Lentini L. ; Melfi R. ; Di Leonardo A. ; Spinello A. ; et al. Mol. Pharmaceutics 
2014 , 11 , 653 –664 . 10.1021/mp400230s .
a Kesornpun C. ; Aree T. ; Mahidol C. ; Ruchirawat S. ; et al. Angew. Chem., Int. Ed. 
2016 , 55 , 3997 –4001 . 10.1002/anie.201511730 . b Pace A. ; Buscemi S. ; Piccionello A. P. ; Pibiri I. 
Adv. Heterocycl. Chem. 
2015 , 116 , 85 –136 . 10.1016/bs.aihch.2015.05.001 . c Pace A. ; Pierro P. 
Org. Biomol. Chem. 
2009 , 7 , 4337 –4348 . 10.1039/b908937c .19830279 
a Bhat S. V. ; Robinson D. ; Moses J. E. ; Sharma P. 
Org. Lett. 
2016 , 18 , 1100 –1103 . 10.1021/acs.orglett.6b00203 .26889784  b Kotipalli T. ; Kavala V. ; Konala A. ; Janreddy D. ; et al. Adv.
Synth. Catal. 
2016 , 358 , 2652 –2660 . 10.1002/adsc.201600274 . c Mercalli V. ; Massarotti A. ; Varese M. ; Giustiniano M. ; et al. J. Org.
Chem. 
2015 , 80 , 9652 –9661 . 10.1021/acs.joc.5b01676 .26360930  d Ovdiichuk O. V. ; Hordiyenko O. V. ; Arrault A. 
Tetrahedron 
2016 , 72 , 3427 –3435 . 10.1016/j.tet.2016.04.069 .
a Bolotin D.
S. ; Kulish K. I. ; Bokach N. A. ; Starova G. L. ; et al. Inorg. Chem. 
2014 , 53 , 10312 –10324 . 10.1021/ic501333s .25198538  b Zora M. ; Kivrak A. ; Kelgokmen Y. 
J. Organomet. Chem. 
2014 , 759 , 67 –73 . 10.1016/j.jorganchem.2014.02.018 . c Andersen T. L. ; Caneschi W. ; Ayoub A. ; Lindhardt A. T. ; et al. Adv.
Synth. Catal. 
2014 , 356 , 3074 –3082 . 10.1002/adsc.201400487 . d Melekhova A. A. ; Smirnov A. S. ; Novikov A. S. ; Panikorovskii T. L. ; Bokach N. A. ; Kukushkin V. Y. 
ACS Omega 
2017 , 2 , 1380 –1391 . 10.1021/acsomega.7b00130 .31457510 
a Miller D. J. ; Scrowston R. M. ; Kennewell P. D. ; Westwood R. 
Tetrahedron 
1994 , 50 , 5159 –5168 . 10.1016/s0040-4020(01)90426-0 . b Huang X. ; Pissarnitski D. ; Li H. ; Asberom T. ; et al. Tetrahedron
Lett. 
2012 , 53 , 6451 –6455 . 10.1016/j.tetlet.2012.09.070 . c Li X. ; Zheng A. ; Liu B. ; Li G. ; et al. J. Heterocycl.
Chem. 
2011 , 48 , 776 –779 . 10.1002/jhet.578 . d Altuğ C. ; Dürüst Y. ; Elliott M. C. ; Kariuki B. M. ; et al. Org. Biomol. Chem. 
2010 , 8 , 4978 –4986 . 10.1039/c0ob00286k .20820661  e Corsaro A. ; Pistara V. ; Rescifina A. ; Chiacchio M. A. ; et al. Heterocycles 
2005 , 65 , 1079 –1097 . 10.3987/com-05-10342 . f Dawood K. M. 
Heteroat. Chem. 
2004 , 15 , 432 –436 . 10.1002/hc.20037 . g Corsaro A. ; Perrini G. ; Pistarà V. ; Quadrelli P. ; et al. Tetrahedron 
1996 , 52 , 6421 –6436 . 10.1016/0040-4020(96)00276-1 . h Coutouli-Argyropoulou E. ; Malamidou-Xenikaki E. ; Mentzafos D. ; Terzis A. 
J. Heterocycl. Chem. 
1990 , 27 , 1185 –1189 . 10.1002/jhet.5570270505 . i Malamidou-Xenikaki E. ; Coutouli-Argyropoulou E. 
Tetrahedron 
1990 , 46 , 7865 –7872 . 10.1016/s0040-4020(01)90084-5 . j Luheshi A.-B. N. ; Smalley R. K. ; Kennewell P. D. ; Westwood R. 
Tetrahedron Lett. 
1990 , 31 , 123 –126 . 10.1016/s0040-4039(00)94351-x . k Hemming K. ; Luheshi A.-B. N. ; Redhouse A. D. ; Smalley R. K. ; et al. Tetrahedron 
1993 , 49 , 4383 –4408 . 10.1016/s0040-4020(01)85755-0 . l Hemming K. ; Khan M. N. ; O’Gorman P. A. ; Pitard A. 
Tetrahedron 
2013 , 69 , 1279 –1284 . 10.1016/j.tet.2012.12.007 .
a Sumpter W.
C. 
Chem. Rev. 
1944 , 34 , 393 –434 . 10.1021/cr60109a003 . b da Silva J. F. M. ; Garden S. J. ; Pinto A. C. 
J. Braz. Chem. Soc. 
2001 , 12 , 273 –324 . 10.1590/s0103-50532001000300002 .
a Zi Y. ; Cai Z.-J. ; Wang S.-Y. ; Ji S.-J. 
Org.
Lett. 
2014 , 16 , 3094 –3097 . 10.1021/ol501203q .24850466  b Huang P.-C. ; Gandeepan P. ; Cheng C.-H. 
Chem. Commun. 
2013 , 49 , 8540 –8542 . 10.1039/c3cc44435j . c Chen S. ; Liu Z. ; Shi E. ; Chen L. ; et al. Org.
Lett. 
2011 , 13 , 2274 –2277 . 10.1021/ol200716d .21488675  d Chouhan M. ; Senwar K. R. ; Sharma R. ; Grover V. ; et al. Green
Chem. 
2011 , 13 , 2553 –2560 . 10.1039/c1gc15416h .
a Boruah M. ; Konwar D. 
Synth. Commun. 
2012 , 42 , 3261 –3268 . 10.1080/00397911.2011.558665 . b Dubrovskiy A. V. ; Larock R. C. 
Org. Lett. 
2010 , 12 , 1180 –1183 . 10.1021/ol902921s .20184347 
Kassaee M. Z. ; Arshadi S. ; Haerizade B. N. ; Vessally E. 
J. Mol. Struct.: THEOCHEM 
2005 , 731 , 29 –37 . 10.1016/j.theochem.2005.02.087 .
a Xie S. ; Lopez S. A. ; Ramström O. ; Yan M. ; et al. J. Am. Chem. Soc. 
2015 , 137 , 2958 –2966 . 10.1021/ja511457g .25553488  b Aronoff M.
R. ; Gold B. ; Raines R. T. 
Org. Lett. 
2016 , 18 , 1538 –1541 . 10.1021/acs.orglett.6b00278 .26981746  c Sayin K. ; Kurtoglu N. ; Kose M. ; Karakas D. ; et al. J. Mol.
Struct. 
2016 , 1119 , 413 –422 . 10.1016/j.molstruc.2016.04.097 . d Khojastehnezhad A. ; Eshghi H. ; Moeinpour F. ; Bakavoli M. ; et al. Struct. Chem. 
2016 , 27 , 1041 –1047 . 10.1007/s11224-015-0703-8 .

